Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere

Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that results from the Phase III TANGO 2 study of Vabomere (meropenem and vaborbactam) have been published in Infectious Diseases and Therapy.

As quoted in the press release:

Vabomere was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible Enterobacteriaceae. The Vabomere approval was supported by TANGO 1, a Phase III, multi-center, randomized, double-blind, double-dummy study evaluating the efficacy, safety and tolerability of Vabomere compared to piperacillin-tazobactam in the treatment of cUTI. The Vabomere development program was supported by a cost-share contract with the Biomedical Advanced Research and Development Authority (BARDA).

Targeting Antibiotic Non-susceptible Gram-negative Organisms (TANGO) 2 was a multi-center, randomized, open-label, pathogen-directed, descriptive study of monotherapy VABOMERE 4 g IV infused every eight hours over three hours for up to 14 days compared with BAT for the treatment of patients with cUTI, acute pyelonephritis (AP), complicated intra-abdominal infection (cIAI), hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), and bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE).

Click here to read the full press release.